Bletinib ameliorates neutrophilic inflammation and lung injury by inhibiting Src family kinase phosphorylation and activity
Open Access
- 14 July 2021
- journal article
- research article
- Published by Wiley in British Journal of Pharmacology
- Vol. 178 (20) , 4069-4084
Abstract
Background and Purpose: Neutrophil overactivation is crucial in the pathogenesis of acute lung injury (ALI). Bletinib (3,3′‐dihydroxy‐2′,6′‐bis(p‐hydroxybenzyl)‐5‐methoxybibenzyl), a natural bibenzyl, extracted from the Bletilla plant, exhibits anti‐inflammatory, antibacterial, and antimitotic effects. In this study, we evaluated the therapeutic effects of bletinib in human neutrophilic inflammation and LPS‐mediated ALI in mice.Experimental Approach: In human neutrophils activated with the formyl peptide (fMLP), we assessed integrin expression, superoxide anion production, degranulation, neutrophil extracellular trap (NET) formation, and adhesion through flow cytometry, spectrophotometry, and immunofluorescence microscopy. Immunoblotting was used to measure phosphorylation of Src family kinases (SFKs) and downstream proteins. Finally, a LPS‐induced ALI model in male BALB/c mice was used to investigate the potential therapeutic effects of bletinib treatment.Key Results: In activated human neutrophils, bletinib reduced degranulation, respiratory burst, NET formation, adhesion, migration, and integrin expression; suppressed the enzymic activity of SFKs, including Src, Lyn, Fgr, and Hck; and inhibited the phosphorylation of SFKs as well as Vav and Bruton's tyrosine kinase (Btk). In mice with ALI, the pulmonary sections demonstrated considerable amelioration of prominent inflammatory changes, such as haemorrhage, pulmonary oedema, and neutrophil infiltration, after bletinib treatment.Conclusion and Implications: Bletinib regulates neutrophilic inflammation by inhibiting the SFK‐Btk‐Vav pathway. Bletinib ameliorates LPS‐induced ALI in mice. Further biochemical optimisation of bletinib may be a promising strategy for the development of novel therapeutic agents for inflammatory diseases.Keywords
All Related Versions
Funding Information
- Ministry of Science and Technology, Taiwan (MOST 106‐2320‐B‐255‐003‐MY3, MOST 108‐2320‐B‐126‐001, MOST 108‐2320‐B‐255‐003‐MY3, MOST 109‐2320‐B‐126‐003‐MY3, MOST 109‐2327‐B‐182‐002)
This publication has 87 references indexed in Scilit:
- Multiple Roles for Neutrophils in AtherosclerosisCirculation Research, 2012
- Neutrophils in the activation and regulation of innate and adaptive immunityNature Reviews Immunology, 2011
- Neutrophil extracellular trap cell death requires both autophagy and superoxide generationCell Research, 2010
- Src kinase up-regulates the ERK cascade through inactivation of protein phosphatase 2A following cerebral ischemiaBMC Neuroscience, 2009
- Src family kinases mediate neutrophil adhesion to adherent plateletsBlood, 2006
- Overexpression of podoplanin in oral cancer and its association with poor clinical outcomeCancer, 2006
- Neutrophil Extracellular Traps Kill BacteriaScience, 2004
- Enhanced neutrophil response in chronic obstructive pulmonary diseaseThorax, 2001
- Discovery of a Novel, Potent, and Src Family-selective Tyrosine Kinase InhibitorJournal of Biological Chemistry, 1996
- The anti mac-1 monoclonal antibody inhibits neutrophil sequestration in lung and liver in a septic murine modelClinical Immunology and Immunopathology, 1991